Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

172
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
172
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

327
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
327
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

245
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
245
Actuarial Approach01:20

Actuarial Approach

108
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
108
Cancer Survival Analysis01:21

Cancer Survival Analysis

410
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
410
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

217
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
217

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CT Perfusion Blood Flow Provides an Early Response Marker for Progression-free Survival in a Prospective Randomized Clinical Trial of Metastatic Renal Cell Carcinoma.

Technology in cancer research & treatment·2026
Same author

Pretreatment Risk Model for Radiation-Induced Lymphopenia Is Associated With Adjuvant Durvalumab Efficacy in Patients With Unresectable Stage III NSCLC.

International journal of radiation oncology, biology, physics·2026
Same author

PD-L1 subpopulations of metastatic urothelial carcinoma demonstrate heterogeneity to chemotherapy: an integrated analysis of digitized trial results.

Cancer metastasis reviews·2026
Same author

Master Protocol Design With Hybrid Control for Efficient Early-Phase Trial Consolidation.

JCO precision oncology·2025
Same author

Bayesian network meta-regression for aggregate ordinal outcomes with imprecise categories.

Journal of biopharmaceutical statistics·2025
Same author

A patient similarity-embedded Bayesian approach to prognostic biomarker inference with application to thoracic cancer immunity.

Journal of the Royal Statistical Society. Series C, Applied statistics·2025
Same journal

Explainable incremental-value analysis of apparent diffusion coefficient and arterial spin labeling radiomics for ATRX status prediction in glioblastoma.

Frontiers in oncology·2026
Same journal

Study-level factors associated with hematoma after ultrasound-guided vacuum-assisted breast lesion excision: a systematic review and meta-analysis using a T-P-B framework.

Frontiers in oncology·2026
Same journal

Feasibility and strategy analysis of radiotherapy consolidation following immunotherapy for stage IV esophageal squamous cell carcinoma.

Frontiers in oncology·2026
Same journal

Anastomosing hemangioma of the kidney: a case report.

Frontiers in oncology·2026
Same journal

Machine learning-based prediction of prolonged air leak after uniportal video-assisted thoracic surgery segmentectomy.

Frontiers in oncology·2026
Same journal

Past present and future of radiosensitization in cervical cancer.

Frontiers in oncology·2026
See all related articles

Related Experiment Video

Updated: Aug 11, 2025

Monitoring Neuronal Survival via Longitudinal Fluorescence Microscopy
07:02

Monitoring Neuronal Survival via Longitudinal Fluorescence Microscopy

Published on: January 19, 2019

6.5K

Landmark mediation survival analysis using longitudinal surrogate.

Jie Zhou1, Xun Jiang2, H Amy Xia2

  • 1Department of Biostatistics and Pharmacometrics, Neuroscience Global Drug Development, Novartis, East Hanover, NJ, United States.

Frontiers in Oncology
|February 3, 2023
PubMed
Summary
This summary is machine-generated.

This study introduces a new statistical framework for cancer clinical trials, incorporating longitudinal tumor burden data to better predict survival outcomes. The method enhances the analysis of treatment efficacy beyond traditional binary response rates.

Keywords:
RECISTfunctional principal component analysislandmark analysislongitudinal analysismediation analysisoncology

More Related Videos

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.3K
Measurement of Lifespan in Drosophila melanogaster
10:00

Measurement of Lifespan in Drosophila melanogaster

Published on: January 7, 2013

34.5K

Related Experiment Videos

Last Updated: Aug 11, 2025

Monitoring Neuronal Survival via Longitudinal Fluorescence Microscopy
07:02

Monitoring Neuronal Survival via Longitudinal Fluorescence Microscopy

Published on: January 19, 2019

6.5K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.3K
Measurement of Lifespan in Drosophila melanogaster
10:00

Measurement of Lifespan in Drosophila melanogaster

Published on: January 7, 2013

34.5K

Area of Science:

  • Oncology
  • Biostatistics
  • Clinical Trial Design

Background:

  • Cancer clinical trials assess tumor burden using radiographic measurements.
  • Current statistical methods often simplify tumor burden to binary outcomes (e.g., objective response rate), limiting analysis.
  • Longitudinal tumor burden data are underutilized in mediation analyses linking treatment, tumor burden, and survival.

Purpose of the Study:

  • To present a novel framework for landmark mediation survival analyses that integrates longitudinal tumor burden assessments.
  • To develop R-squared effect-size measures for quantifying survival treatment mediation effects using longitudinal predictors.
  • To improve the statistical modeling of cancer treatment efficacy and survival prediction.

Main Methods:

  • Development of a framework for landmark mediation survival analyses.
  • Introduction of R-squared effect-size measures for longitudinal predictors.
  • Application of the framework to two colorectal cancer trials.
  • Comparison of survival prediction with and without longitudinal analysis.
  • Simulation studies to identify optimal use cases for longitudinal analysis.

Main Results:

  • The proposed framework effectively incorporates longitudinal tumor burden data into survival analyses.
  • R-squared effect-size measures provide quantitative insights into treatment mediation effects.
  • Analyses demonstrated the utility of the method in colorectal cancer trials.
  • Longitudinal analysis improved survival prediction in specific scenarios.

Conclusions:

  • Integrating longitudinal tumor burden data into statistical models offers a more comprehensive evaluation of cancer treatment efficacy.
  • The developed framework and effect-size measures enhance the characterization of treatment-survival relationships.
  • This approach provides a more nuanced understanding of drug activity and patient outcomes in clinical trials.